USA – Mead Johnson, a leading manufacturer of infant formula, has launched a new infant formula under its Enfamil brand that contains A2 milk proteins, in an effort to provide a gentle option for a baby’s digestive system.
With its new FDA-regulated infant formula, Enfamil aims to meet the increasing demand for A2 milk as according to the brand, studies in young children and adults suggests the ingredient is less likely to be associated with digestive discomfort.
According to Enfamil, DHA is an important Omega‐3 nutrient that’s a key building block for a baby’s brain and eye development. The formula – which is said to be recommended by paediatricians – does not contain any added table sugar, corn, artificial growth hormones, antibiotics, or GMOs.
“If you’re looking for an FDA regulated formula that’s easily accessible that has A2 proteins from European cows’ milk and a global expert recommended amount of DHA, Enfamil Premium A2 Infant Formula may be a good choice for your little one.”
Dr Christina Valentine – medical director, RB Nutrition
“While parents may believe European baby formula brands are ‘cleaner’ than American companies, the lack of FDA oversight is concerning,” said Dr Christina Valentine, medical director at RB Nutrition.
“If you’re looking for an FDA regulated formula that’s easily accessible that has A2 proteins from European cows’ milk and a global expert recommended amount of DHA, Enfamil Premium A2 Infant Formula may be a good choice for your little one.”
Available in the US, Enfamil Premium A2 Infant Formula claims to be the only formula that includes both ‘easy-to-digest’ A2 milk proteins sourced from European cows and DHA in a global expert-recommended amount (0.2%-0.36%).
Enfamil’s new formula is made using proteins from the milk of cows that still naturally produce the A2 protein, which the brand claims is similar to that found in breast milk.
Mead Johnson & Company, LLC is an American division and subsidiary of Anglo-Dutch company Reckitt Benckiser. It is a leading manufacturer of infant formula both domestically and globally with its flagship product Enfamil.
The company dates back to a firm created by Edward Mead Johnson, one of the co-founders of Johnson & Johnson, who created his own business in 1895, which was renamed Mead Johnson & Company in 1905.
The company was majority owned by Bristol-Myers Squibb after an acquisition in 1967 but was spun-off in 2009 as an independent firm.
In February 2017, British consumer goods company Reckitt Benckiser (RB) bid US$16.7 billion for the company.
On June 15, 2017 MJN announced that its merger with RB has been completed. As a result, MJN’s common stock is no longer traded on the New York Stock Exchange, effective the announcement date.
Liked this article? Subscribe to Food Business Africa News, our regular email newsletters with the latest news insights from Africa and the World’s food and agro industry. SUBSCRIBE HERE
